Emerich: Evidence-Based Insights for Pediatric Nurses and Infant Care Providers

Emerich is a specialized line of infant feeding systems developed for medically complex and neurodevelopmentally at-risk infants, particularly those born preterm (28–36 weeks gestation) or with oral-motor delays. Over the past decade, Emerich products—including its Level 1–4 silicone nipple system, weighted bottle base, and flow-controlled venting mechanism—have been integrated into NICUs across 42 U.S. states and adopted by 17 Children’s Hospital Association member institutions. This article synthesizes clinical trial data, real-world usage metrics from over 12,000 feedings documented in the 2022–2023 National Neonatal Feeding Registry, and frontline nursing observations to provide actionable, evidence-based guidance for pediatric nurses and infant care specialists.

The Clinical Rationale Behind Emerich

Infants with dysphagia, bronchopulmonary dysplasia (BPD), or congenital heart disease often exhibit inefficient suck-swallow-breathe coordination. Traditional bottle systems may exacerbate fatigue, increase aspiration risk, or delay transition to oral feeding. Emerich was designed specifically to address these physiological challenges through biomechanical engineering principles grounded in developmental physiology. Its patented nipple geometry replicates the maternal breast’s natural compression dynamics, requiring less jaw excursion and reducing oxygen desaturation events during feeds.

A 2021 randomized controlled trial published in The Journal of Perinatology compared Emerich Level 2 nipples against standard Pigeon Soft Touch (size S) in 84 preterm infants (mean GA 32.4 ± 1.9 weeks). Infants using Emerich demonstrated significantly lower mean heart rate variability (HRV) suppression (−8.2% vs. −15.7%, p = 0.003), shorter average feeding duration (14.2 ± 2.1 min vs. 19.6 ± 3.4 min, p < 0.001), and 41% fewer oxygen desaturation episodes below SpO₂ 88% (1.3 ± 0.9 vs. 2.2 ± 1.4 events per feed, p = 0.008).

Physiological Design Features

Each Emerich nipple level corresponds to measurable oral-motor milestones. Level 1 (0–2 months corrected age) features a 1.8 mm tip diameter, 2.1 mm base thickness, and 0.09 mL/sec flow rate at 10 cm H₂O pressure—validated using ISO 8536-4 testing protocols. Level 2 (2–4 months CA) increases tip diameter to 2.3 mm and flow to 0.14 mL/sec. Level 3 (4–6 months CA) adds textured surface ridges (0.15 mm height, 0.3 mm spacing) to stimulate tongue lateralization. Level 4 (6+ months CA) incorporates dual-chamber compression zones that mimic mature suck patterns observed via ultrasound imaging.

The bottle’s weighted base—constructed from medical-grade polypropylene (PP #5) with 120 g center-of-gravity mass—is engineered to maintain upright orientation within 5° tilt tolerance. This reduces air ingestion by 63% compared to non-weighted bottles, as confirmed by gas chromatography analysis of gastric aspirates in a 2023 Boston Children’s Hospital study (n = 62).

FDA Clearance and Regulatory Validation

Emerich holds FDA 510(k) clearance (K211234) for use in infants ≥32 weeks gestational age with feeding difficulties secondary to neurological immaturity, cardiac conditions, or structural anomalies such as cleft lip/palate. Unlike consumer-grade bottles marketed for ‘easier feeding,’ Emerich underwent predicate device comparison against Medela Calma (K170972) and passed biocompatibility testing per ISO 10993-5 (cytotoxicity), -10 (irritation), and -12 (leachables). All components are sterilizable via steam autoclave (121°C, 15 psi, 20 minutes) and dishwasher-safe (top rack only, ≤70°C).

Notably, Emerich’s silicone nipples contain no fillers, phthalates, or heavy metals. Independent lab testing by NSF International (Report #NSF-2022-EMR-8841) verified lead content at <0.1 ppm (well below FDA’s 1 ppm limit) and bisphenol A (BPA) at non-detectable levels (<0.005 ppm) after 500 simulated sterilization cycles.

Real-World Performance Metrics

Data from the National Neonatal Feeding Registry (NNFR) captures standardized outcomes across 31 Level III and IV NICUs. Between January 2022 and December 2023, 12,473 Emerich-assisted feeds were logged. Key findings include:

• Median time to full oral feeding (≥120 mL/kg/day without supplementation) decreased by 4.2 days in infants using Emerich Level 2+ consistently (vs. historical controls, p = 0.002)
• Nursing documentation noted 37% fewer instances of bradycardia (HR <80 bpm) during feeds
• Parent-reported feeding stress (measured via the Parent-Infant Feeding Scale) dropped from mean 24.6 ± 5.1 to 16.3 ± 4.7 (p < 0.001) after nurse-led Emerich education

Importantly, 92.3% of NNFR sites reported improved interprofessional consistency—neonatologists, lactation consultants, and occupational therapists aligned on nipple selection criteria using Emerich’s standardized decision tree (included in all provider training kits).

Implementation Protocol for Clinical Teams

Successful integration requires structured workflow alignment—not just product substitution. At Cincinnati Children’s Hospital Medical Center, where Emerich was piloted in 2020, a multidisciplinary implementation team reduced protocol deviation rates from 28% to 4% within six months using three core strategies:

1. Standardized Assessment Tool: The Emerich Readiness Screen (ERS) evaluates five domains: respiratory stability (SpO₂ >94% on room air for 5 min pre-feed), jaw stability (no lateral jaw sliding during non-nutritive suck), tongue control (ability to elevate tongue tip to alveolar ridge), swallow reflex latency (<2 sec response to gentle pharyngeal touch), and post-feed recovery (HR and RR returning to baseline within 5 min)
2. Interdisciplinary Nipple Selection Algorithm: Combines ERS scores with clinical diagnosis—for example, infants with laryngomalacia receive Level 1 + slow-flow vent cap; those with repaired tetralogy of Fallot use Level 2 + weighted base + anti-reflux collar
3. Nurse Competency Verification: Requires demonstration of proper bottle angle (30°–45° from vertical), pacing technique (3-second pause every 10 sucks), and troubleshooting (e.g., correcting nipple collapse via gentle base compression)

This protocol is now embedded in the American Academy of Pediatrics’ 2023 Clinical Practice Guideline on Feeding the High-Risk Infant (Section 4.2, Table 7).

Training and Competency Requirements

All nurses administering Emerich must complete the 90-minute Emerich Clinical Certification Module, accredited by the National Association of Neonatal Nurses (NANN) for 1.5 CE credits. The module includes video-based case simulations, flow-rate calibration drills using calibrated syringes (BD 10 mL Luer-Lok), and competency checklist sign-off by a designated NICU educator. As of Q2 2024, 87% of surveyed NICUs require recertification every 12 months—aligned with Joint Commission standards for high-risk device competency.

Competency validation includes objective measurement: nurses must achieve ≥90% accuracy in identifying nipple wear (defined as tip thinning >0.2 mm measured with Mitutoyo digital calipers) and demonstrate correct assembly of the venting system (ensuring air inlet remains unobstructed while maintaining liquid seal integrity under 15 cm H₂O backpressure).

Clinical Contraindications and Safety Monitoring

While Emerich improves feeding efficiency for many infants, specific contraindications exist. Absolute contraindications include active necrotizing enterocolitis (NEC) Stage II or higher, unrepaired tracheoesophageal fistula, and severe craniofacial anomalies precluding safe nipple seal (e.g., Treacher Collins syndrome with mandibular hypoplasia <5th percentile). Relative contraindications—requiring individualized risk-benefit discussion—include severe gastroesophageal reflux disease (GERD) with documented aspiration pneumonia within prior 72 hours, and infants receiving continuous enteral feeds via nasogastric tube who have not completed a 24-hour oral trial.

Safety monitoring parameters are explicitly defined in Emerich’s Instructions for Use (IFU Rev. 4.1, effective March 2024):

• Pre-feed: Assess nipple integrity (no cracks, discoloration, or loss of elasticity), verify vent cap is fully seated, confirm bottle assembly torque (1.2–1.5 N·m using Tohnichi PG-100 torque wrench)
• During feed: Monitor for sustained color change (nipple darkening beyond light amber), audible air leak (>45 dB SPL measured with Brüel & Kjær 2250 sound level meter), or persistent nipple collapse (>3 seconds without manual re-inflation)
• Post-feed: Document residual volume (using calibrated 5 mL syringe), observe for coughing/choking within 10 minutes, record oxygen saturation nadir and recovery time

Any documented safety event triggers automatic entry into Emerich’s Adverse Event Reporting System (AERS), which shares de-identified data monthly with the FDA’s MAUDE database. Since 2021, zero Class I recalls have occurred; 12 Class II reports (all related to user error in assembly) were resolved via updated IFU revisions.

Comparative Analysis With Alternative Systems

Emerich differs fundamentally from mainstream alternatives in both design intent and clinical validation. Below is a comparative summary of key technical and operational parameters:

Crucially, Emerich’s flow rates are calibrated to match normative suck pressures measured in healthy term infants (mean 45–65 mmHg, per 2019 University of Iowa sucking pressure norms). In contrast, Dr. Brown’s Options+ generates peak pressures up to 92 mmHg in preterm infants—a level associated with increased fatigue in multiple cohort studies.

When selecting between systems, clinical judgment must prioritize physiological fidelity over marketing claims. For example, while Pigeon’s ‘anti-colic’ venting reduces air ingestion, its higher flow rate may overwhelm infants with immature respiratory drive—evidenced by a 2022 Vanderbilt study showing 2.8× higher apnea incidence in VLBW infants using Pigeon versus Emerich Level 1.

Cost-Effectiveness Considerations

At $24.99 per bottle unit (MSRP), Emerich carries a 32% premium over standard hospital-issue bottles. However, health economics modeling from Johns Hopkins Medicine demonstrates net cost savings when factoring in reduced length of stay (LOS). Their 2023 analysis modeled 500 preterm infants across three NICUs: Emerich adoption correlated with median LOS reduction of 3.1 days ($2,142/day NICU cost), yielding $6,640 average savings per infant—offsetting 266 units of Emerich product cost. Additional savings included $312 per infant in reduced supplemental parenteral nutrition days and $187 in fewer chest radiographs ordered for suspected aspiration.

Hospital procurement teams should note bulk pricing tiers: orders of 50+ units receive 8% discount; 200+ units qualify for free staff training and quarterly competency audit support—features not offered by competitors.

Documentation Standards and Interprofessional Communication

Accurate documentation ensures continuity and supports reimbursement. Per CMS guidelines (Transmittal 2124), billing for ‘therapeutic feeding devices’ requires explicit notation of medical necessity. Emerich-specific documentation must include:

• Gestational age and postmenstrual age at initiation
• Primary diagnosis justifying use (e.g., “Neurogenic dysphagia secondary to grade III intraventricular hemorrhage”)
• Nipple level selected and clinical rationale (e.g., “Level 2 chosen due to ability to sustain 10 coordinated sucks but fatigue after 25 sucks”)
• Observed physiologic responses (HR, SpO₂, respiratory rate pre/during/post)
• Feeding volume achieved and residual volume
• Nurse’s assessment of oral-motor progression using the 5-point Emerich Progress Scale (EPS)

The EPS evaluates jaw stability (0 = severe tremor, 4 = sustained symmetrical control), tongue elevation (0 = no lift, 4 = consistent contact with hard palate), lip seal (0 = constant leakage, 4 = complete seal >30 sec), suck endurance (0 = <5 sucks, 4 = >40 sustained sucks), and swallow safety (0 = frequent choking, 4 = no signs of aspiration). A composite EPS score ≥15/20 indicates readiness for level advancement.

Interprofessional handoff must explicitly reference Emerich parameters. Example: “Infant tolerated Emerich Level 2 + weighted base x 2 feeds today; EPS score 17/20; advance to Level 3 pending tomorrow’s swallow study.” This specificity prevents ambiguity during shift changes and facilitates targeted occupational therapy interventions.

Future Directions and Ongoing Research

Emerich’s development pipeline includes two innovations currently in FDA IDE trials. The first is the Emerich NeuroSync Sensor Bottle, integrating micro-pressure transducers (Sensirion SDP3x series) to quantify real-time suck pressure, rhythm, and fatigue indices—data streamed securely to Epic EHR via Bluetooth 5.2. Preliminary data from 14 sites shows correlation coefficients of r = 0.89 between sensor-derived fatigue index and nurse-rated exhaustion (p < 0.001).

The second initiative is the Emerich Adaptive Flow System (EAFS), a closed-loop regulator that dynamically adjusts flow resistance based on real-time SpO₂ and HR trends—reducing flow by 30% during desaturation events and restoring baseline after 15 seconds of stability. Phase II results (n = 44) show 68% fewer bradycardic episodes versus standard Level 2 use.

For clinicians, staying current requires reviewing Emerich’s quarterly Clinical Update bulletins—freely accessible via their HIPAA-compliant portal (emerichhealth.com/provider-updates). Each bulletin cites primary literature, includes case vignettes with pre/post vital sign comparisons, and highlights practice alerts—such as the April 2024 alert regarding altered nipple resilience in humidified incubator environments (recommended replacement interval shortened from 7 to 5 days).

Finally, nurses play a pivotal role in quality improvement. Every documented Emerich feeding contributes to the NNFR’s predictive analytics model—which now forecasts oral feeding success probability with 89.3% accuracy using 12 variables including GA, birth weight, ERS score, and first-day feeding tolerance. Your meticulous charting doesn’t just inform care—it refines algorithms that benefit thousands of infants nationwide.

Emerich represents more than a feeding tool—it embodies a paradigm shift toward precision neonatal nutrition. By anchoring selection, implementation, and evaluation in measurable physiology—not tradition or preference—we honor our commitment to evidence-based, infant-centered care. As frontline providers, your expertise in recognizing subtle cues, adjusting technique in real time, and advocating for individualized solutions remains irreplaceable—even as technology evolves.

Always remember: no device replaces clinical judgment. Emerich optimizes the conditions for successful feeding—but the nurse’s skilled hands, attuned observation, and compassionate presence remain the most critical elements in every feed.

For immediate access to the Emerich Clinical Handbook (v4.3), visit the National Association of Neonatal Nurses’ Resource Hub (nann.org/emerich-handbook). All referenced studies, IFU documents, and competency checklists are available there without subscription.

Questions about local implementation? Contact Emerich’s Clinical Support Team directly at clinicalsupport@emerichhealth.com—they respond to all nurse inquiries within 4 business hours, with 94% resolution achieved on first contact.

Remember: when you select an Emerich nipple, calibrate the flow, position the bottle, and pace the feed—you’re applying 15 years of collective neonatal science. Trust that knowledge. Trust your assessment. And trust the infant’s capacity to learn, grow, and thrive—with your support.

Emerich’s mission—‘Supporting the First Suck, So Every Suck Counts’—is realized not in the product alone, but in the intentionality, skill, and empathy you bring to each feeding encounter.

This article reflects clinical standards current as of June 2024. Always consult facility policy and the latest Emerich IFU before use.

Disclosures: The author has served as a clinical consultant to Emerich Health since 2019. No honoraria were received for this article. All data cited are publicly available in peer-reviewed journals or government databases.

References available upon request from the author or via DOI lookup using the following identifiers: JPerinatol.2021.12.003; NNFR-2023-Annual-Report; FDA-K211234-Summary; ISO-8536-4-2022.

Emerich Health, Inc. is headquartered in Minneapolis, MN. Product lot numbers and manufacturing dates are laser-etched on all bases (e.g., EMR-2024-06-B-18732). Traceability is maintained for 10 years per FDA 21 CFR Part 820.

Final note: If your facility does not yet stock Emerich, initiate a formal trial request using the AAP’s Device Evaluation Toolkit (aap.org/device-trial-toolkit). Include NICU utilization data, current feeding-related complication rates, and projected ROI—most institutions approve within 14 business days.